© 2002 by Oxford University Press
Journal of the National Cancer Institute, Vol. 94, No. 13, 981-990,
July 3, 2002
© 2002 Oxford University Press
ARTICLE |
Overdiagnosis Due to Prostate-Specific Antigen Screening: Lessons From U.S. Prostate Cancer Incidence Trends
Affiliations of authors: R. Etzioni, D. di Tommaso, Fred Hutchinson Cancer Research Center, Seattle, WA; D. F. Penson, Veterans Affairs Medical Center, Seattle; J. M. Legler, E. J. Feuer, Applied Research Branch, Cancer Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD; R. Boer, RAND Corporation, Santa Monica, CA; P. H. Gann, Northwestern University Medical School, Chicago, IL.
Correspondence to: Ruth Etzioni, Ph.D., Program in Biostatistics, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. North, MP-665, Seattle, WA 98109–1024 (e-mail: retzioni{at}fhcrc.org).
Background: Overdiagnosis of clinically insignificant prostate cancer is considered a major potential drawback of prostate-specific antigen (PSA) screening. Quantitative estimates of the magnitude of this problem are, however, lacking. We estimated rates of prostate cancer overdiagnosis due to PSA testing that are consistent with the observed incidence of prostate cancer in the United States from 1988 through 1998. Overdiagnosis was defined as the detection of prostate cancer through PSA testing that otherwise would not have been diagnosed within the patient's lifetime. Methods: We developed a computer simulation model of PSA testing and subsequent prostate cancer diagnosis and death from prostate cancer among a hypothetical cohort of two million men who were 60–84 years old in 1988. Given values for the expected lead time—that is, the time by which the test advanced diagnosis—and the expected incidence of prostate cancer in the absence of PSA testing, the model projected the increase in population incidence of prostate cancer associated with PSA testing. By comparing the model-projected incidence with the observed incidence derived from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) registry data, we determined the lead times and corresponding overdiagnosis rates that were consistent with the observed data. Results: SEER data on prostate cancer incidence from 1988 through 1998 were consistent with overdiagnosis rates of approximately 29% for whites and 44% for blacks among men with prostate cancers detected by PSA screening. Conclusions: Among men with prostate cancer that would be detected only at autopsy, these rates correspond to overdiagnosis rates of, at most, 15% in whites and 37% in blacks. The observed trends in prostate cancer incidence are consistent with considerable overdiagnosis among PSA-detected cases. However, the results suggest that the majority of screen-detected cancers diagnosed between 1988 and 1998 would have presented clinically and that only a minority of cases found at autopsy would have been detected by PSA testing.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. M Hoffman Review: little high-quality evidence is available regarding treatments for localised prostate cancer Evid. Based Med., October 1, 2008; 13(5): 139 - 139. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Zuccolo, R. Harris, D. Gunnell, S. Oliver, J. A. Lane, M. Davis, J. Donovan, D. Neal, F. Hamdy, R. Beynon, et al. Height and Prostate Cancer Risk: A Large Nested Case-Control Study (ProtecT) and Meta-analysis Cancer Epidemiol. Biomarkers Prev., September 1, 2008; 17(9): 2325 - 2336. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U.S. Preventive Services Task Force Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement Ann Intern Med, August 5, 2008; 149(3): 185 - 191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Mucci, Y. Pawitan, F. Demichelis, K. Fall, J. R. Stark, H.-O. Adami, S.-O. Andersson, O. Andren, A. Eisenstein, L. Holmberg, et al. Testing a Multigene Signature of Prostate Cancer Death in the Swedish Watchful Waiting Cohort Cancer Epidemiol. Biomarkers Prev., July 1, 2008; 17(7): 1682 - 1688. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Ornish, M. J. M. Magbanua, G. Weidner, V. Weinberg, C. Kemp, C. Green, M. D. Mattie, R. Marlin, J. Simko, K. Shinohara, et al. Changes in prostate gene expression in men undergoing an intensive nutrition and lifestyle intervention PNAS, June 17, 2008; 105(24): 8369 - 8374. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Loeb and W. J. Catalona What to Do with an Abnormal PSA Test Oncologist, March 1, 2008; 13(3): 299 - 305. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. G. Welch, S. Woloshin, and L. M. Schwartz The Sea of Uncertainty Surrounding Ductal Carcinoma In Situ--The Price of Screening Mammography J Natl Cancer Inst, February 20, 2008; 100(4): 228 - 229. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Kakehi, T. Kamoto, T. Shiraishi, O. Ogawa, Y. Suzukamo, S. Fukuhara, Y. Saito, K.-i. Tobisu, T. Kakizoe, T. Shibata, et al. Prospective Evaluation of Selection Criteria for Active Surveillance in Japanese Patients with Stage T1cN0M0 Prostate Cancer Jpn. J. Clin. Oncol., February 12, 2008; (2008) hym161v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Connolly, A. Black, A. Gavin, P. F. Keane, and L. J. Murray Baseline Prostate-Specific Antigen Level and Risk of Prostate Cancer and Prostate-Specific Mortality: Diagnosis Is Dependent on the Intensity of Investigation Cancer Epidemiol. Biomarkers Prev., February 1, 2008; 17(2): 271 - 278. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. C. Walsh, T. L. DeWeese, and M. A. Eisenberger Localized Prostate Cancer N. Engl. J. Med., December 27, 2007; 357(26): 2696 - 2705. [Full Text] [PDF]
|
|
|
|
|
|
R. Kvale, A. Auvinen, H.-O. Adami, A. Klint, E. Hernes, B. Moller, E. Pukkala, H. H. Storm, L. Tryggvadottir, S. Tretli, et al. Interpreting Trends in Prostate Cancer Incidence and Mortality in the Five Nordic Countries J Natl Cancer Inst, December 19, 2007; 99(24): 1881 - 1887. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. G. Welch, S. Woloshin, L. M. Schwartz, L. Gordis, P. C. Gotzsche, R. Harris, B. S. Kramer, and D. F. Ransohoff Overstating the Evidence for Lung Cancer Screening: The International Early Lung Cancer Action Program (I-ELCAP) Study Arch Intern Med, November 26, 2007; 167(21): 2289 - 2295. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Barrette, M. L. Bernstein, L. L. Robison, Y. Samson, J. Brossard, S. Weitzman, and W. G. Woods Incidence of Neuroblastoma After a Screening Program J. Clin. Oncol., November 1, 2007; 25(31): 4929 - 4932. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. D. Etzioni, D. P. Ankerst, N. S. Weiss, L. Y. T. Inoue, and I. M. Thompson Is Prostate-Specific Antigen Velocity Useful in Early Detection of Prostate Cancer? A Critical Appraisal of the Evidence J Natl Cancer Inst, October 17, 2007; 99(20): 1510 - 1515. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-N. Wong, N. Mitra, G. Hudes, J. S. Schwartz, F. Wan, C. Montagnet, and K. Armstrong Outcomes of Treatment vs Observation of Localized Prostate Cancer in Elderly Men--Reply JAMA, April 18, 2007; 297(15): 1652 - 1653. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Adolfsson Commentary: On the incidence of histological prostate cancer and the probable diagnosis of cases with tumours too small to produce symptoms or to attract attention on physical examination--the findings of Dr Arnold Rice Rich Int. J. Epidemiol., April 17, 2007; (2007) dym053v1. [Full Text] [PDF]
|
|
|
|
|
|
A. B Miller Commentary: Implications of the frequent occurrence of occult carcinoma of the prostate Int. J. Epidemiol., April 1, 2007; 36(2): 282 - 284. [Full Text] [PDF]
|
|
|
|
|
|
H. B. Carter, L. Ferrucci, A. Kettermann, P. Landis, J. Wright, J. I. Epstein, B. J. Trock, and E. J. Metter Response: Re: Detection of Life-Threatening Prostate Cancer With Prostate-Specific Antigen Velocity During a Window of Curability J Natl Cancer Inst, March 21, 2007; 99(6): 490 - 490. [Full Text] [PDF]
|
|
|
|
|
|
A. B. Knudsen, P. M. McMahon, and G. S. Gazelle Use of Modeling to Evaluate the Cost-Effectiveness of Cancer Screening Programs J. Clin. Oncol., January 10, 2007; 25(2): 203 - 208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-N. Wong, N. Mitra, G. Hudes, R. Localio, J. S. Schwartz, F. Wan, C. Montagnet, and K. Armstrong Survival Associated With Treatment vs Observation of Localized Prostate Cancer in Elderly Men JAMA, December 13, 2006; 296(22): 2683 - 2693. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Litwin and D. C. Miller Treating Older Men With Prostate Cancer: Survival (or Selection) of the Fittest? JAMA, December 13, 2006; 296(22): 2733 - 2734. [Full Text] [PDF]
|
|
|
|
|
|
D. C. Miller, S. B. Gruber, B. K. Hollenbeck, J. E. Montie, and J. T. Wei Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst, August 16, 2006; 98(16): 1134 - 1141. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Davies and H. G. Welch Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA, May 10, 2006; 295(18): 2164 - 2167. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Hamashima, T. Sobue, Y. Muramatsu, H. Saito, N. Moriyama, and T. Kakizoe Comparison of Observed and Expected Numbers of Detected Cancers in the Research Center for Cancer Prevention and Screening Program Jpn. J. Clin. Oncol., May 1, 2006; 36(5): 301 - 308. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. B. Carter Assessing risk: does this patient have prostate cancer? J Natl Cancer Inst, April 19, 2006; 98(8): 506 - 507. [Full Text] [PDF]
|
|
|
|
|
|
R. M. Hoffman Viewpoint: limiting prostate cancer screening. Ann Intern Med, March 21, 2006; 144(6): 438 - 440. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Warlick, B. J. Trock, P. Landis, J. I. Epstein, and H. B. Carter Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst, March 1, 2006; 98(5): 355 - 357. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. K. Gwede and R. J. McDermott Prostate Cancer Screening Decision Making Under Controversy: Implications for Health Promotion Practice Health Promot Pract, January 1, 2006; 7(1): 134 - 146. [Abstract] [PDF]
|
|
|
|
|
|
X. Gao, M. P. LaValley, and K. L. Tucker Prospective Studies of Dairy Product and Calcium Intakes and Prostate Cancer Risk: A Meta-Analysis J Natl Cancer Inst, December 7, 2005; 97(23): 1768 - 1777. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Cooperberg, J. W. Moul, and P. R. Carroll The Changing Face of Prostate Cancer J. Clin. Oncol., November 10, 2005; 23(32): 8146 - 8151. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. K. Edwards, M. L. Brown, P. A. Wingo, H. L. Howe, E. Ward, L. A. G. Ries, D. Schrag, P. M. Jamison, A. Jemal, X. C. Wu, et al. Annual Report to the Nation on the Status of Cancer, 1975-2002, Featuring Population-Based Trends in Cancer Treatment J Natl Cancer Inst, October 5, 2005; 97(19): 1407 - 1427. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Soderstrom, W. G. Woods, M. Bernstein, L. L. Robison, M. Tuchman, and B. Lemieux Health and Economic Benefits of Well-Designed Evaluations: Some Lessons From Evaluating Neuroblastoma Screening J Natl Cancer Inst, August 3, 2005; 97(15): 1118 - 1124. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Garzotto, T. M. Beer, R. G. Hudson, L. Peters, Y.-C. Hsieh, E. Barrera, T. Klein, and M. Mori Improved Detection of Prostate Cancer Using Classification and Regression Tree Analysis J. Clin. Oncol., July 1, 2005; 23(19): 4322 - 4329. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. B. Sehgal, I. Gondal, and L. S. Dooley Collateral missing value imputation: a new robust missing value estimation algorithm for microarray data Bioinformatics, May 15, 2005; 21(10): 2417 - 2423. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. H. Gann and M. Han The Natural History of Clinically Localized Prostate Cancer JAMA, May 4, 2005; 293(17): 2149 - 2151. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Tseng, R. A Breslow, B. I Graubard, and R. G Ziegler Dairy, calcium, and vitamin D intakes and prostate cancer risk in the National Health and Nutrition Examination Epidemiologic Follow-up Study cohort Am. J. Clinical Nutrition, May 1, 2005; 81(5): 1147 - 1154. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Wright, D. K. Han, and R. Aebersold Mass Spectrometry-based Expression Profiling of Clinical Prostate Cancer Mol. Cell. Proteomics, April 1, 2005; 4(4): 545 - 554. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Pohl and H. G. Welch The Role of Overdiagnosis and Reclassification in the Marked Increase of Esophageal Adenocarcinoma Incidence J Natl Cancer Inst, January 19, 2005; 97(2): 142 - 146. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. W. Brawley and B. S. Kramer Cancer Screening in Theory and in Practice J. Clin. Oncol., January 10, 2005; 23(2): 293 - 300. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. L. Parnes, I. M. Thompson, and L. G. Ford Prevention of Hormone-Related Cancers: Prostate Cancer J. Clin. Oncol., January 10, 2005; 23(2): 368 - 377. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. K. Johnson, F. D. Gilliland, R. M. Hoffman, D. Deapen, D. F. Penson, J. L. Stanford, P. C. Albertsen, and A. S. Hamilton Racial/Ethnic Differences in Functional Outcomes in the 5 Years After Diagnosis of Localized Prostate Cancer J. Clin. Oncol., October 15, 2004; 22(20): 4193 - 4201. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Olano Natural History of Early Localized Prostate Cancer JAMA, October 6, 2004; 292(13): 1549 - 1549. [Full Text] [PDF]
|
|
|
|
|
|
C. Bermejo, A. R. Kristal, S. B. Zeliadt, S. Ramsey, and I. M. Thompson Localized Prostate Cancer: Quality of Life Meets Whitmore's Legacy J Natl Cancer Inst, September 15, 2004; 96(18): 1348 - 1349. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Barratt, L. Trevena, H. M Davey, and K. McCaffery Use of decision aids to support informed choices about screening BMJ, August 28, 2004; 329(7464): 507 - 510. [Full Text] [PDF]
|
|
|
|
|
|
M. Eisenberger and A. Partin Progress toward Identifying Aggressive Prostate Cancer N. Engl. J. Med., July 8, 2004; 351(2): 180 - 181. [Full Text] [PDF]
|
|
|
|
|
|
J. J Fenton and J. G Elmore Balancing mammography's benefits and harms BMJ, June 12, 2004; 328(7453): E301 - E302. [Full Text] [PDF]
|
|
|
|
|
|
H. B. Carter and W. B. Isaacs Improved Biomarkers for Prostate Cancer: A Definite Need J Natl Cancer Inst, June 2, 2004; 96(11): 813 - 815. [Full Text] [PDF]
|
|
|
|
|
|
M. R. Cooperberg, D. P. Lubeck, M. V. Meng, S. S. Mehta, and P. R. Carroll The Changing Face of Low-Risk Prostate Cancer: Trends in Clinical Presentation and Primary Management J. Clin. Oncol., June 1, 2004; 22(11): 2141 - 2149. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.-H. Zahl, B. H. Strand, and J. Maehlen Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study BMJ, April 17, 2004; 328(7445): 921 - 924. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Yegnasubramanian, J. Kowalski, M. L. Gonzalgo, M. Zahurak, S. Piantadosi, P. C. Walsh, G. S. Bova, A. M. De Marzo, W. B. Isaacs, and W. G. Nelson Hypermethylation of CpG Islands in Primary and Metastatic Human Prostate Cancer Cancer Res., March 15, 2004; 64(6): 1975 - 1986. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Tseng, R. A. Breslow, R. F. DeVellis, and R. G. Ziegler Dietary Patterns and Prostate Cancer Risk in the National Health and Nutrition Examination Survey Epidemiological Follow-up Study Cohort Cancer Epidemiol. Biomarkers Prev., January 1, 2004; 13(1): 71 - 77. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. K. Weir, M. J. Thun, B. F. Hankey, L. A. G. Ries, H. L. Howe, P. A. Wingo, A. Jemal, E. Ward, R. N. Anderson, and B. K. Edwards Annual Report to the Nation on the Status of Cancer, 1975-2000, Featuring the Uses of Surveillance Data for Cancer Prevention and Control J Natl Cancer Inst, September 3, 2003; 95(17): 1276 - 1299. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Draisma, R. Boer, S. J. Otto, I. W. van der Cruijsen, R. A. M. Damhuis, F. H. Schroder, and H. J. de Koning Lead Times and Overdetection Due to Prostate-Specific Antigen Screening: Estimates From the European Randomized Study of Screening for Prostate Cancer J Natl Cancer Inst, June 18, 2003; 95(12): 868 - 878. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. T. Posey, M. S. Soloway, S. Ekici, M. Sofer, F. Civantos, R. C. Duncan, and V. B. Lokeshwar Evaluation of the Prognostic Potential of Hyaluronic Acid and Hyaluronidase (HYAL1) for Prostate Cancer Cancer Res., May 15, 2003; 63(10): 2638 - 2644. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Rhodes, M. G. Sanda, A. P. Otte, A. M. Chinnaiyan, and M. A. Rubin Multiplex Biomarker Approach for Determining Risk of Prostate-Specific Antigen-Defined Recurrence of Prostate Cancer J Natl Cancer Inst, May 7, 2003; 95(9): 661 - 668. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Hoffman An Argument Against Routine Prostate Cancer Screening Arch Intern Med, March 24, 2003; 163(6): 663 - 665. [Full Text] [PDF]
|
|
|
|
|
|
Y. Kakehi Watchful Waiting as a Treatment Option for Localized Prostate Cancer in the PSA Era Jpn. J. Clin. Oncol., January 1, 2003; 33(1): 1 - 5. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Josefson PSA screening leads to overdiagnosis, study says BMJ, July 13, 2002; 325(7355): 61 - 61. [Full Text] [PDF]
|
|
|
|
|
|
S.-L. Yao and G. Lu-Yao Understanding and Appreciating Overdiagnosis in the PSA Era J Natl Cancer Inst, July 3, 2002; 94(13): 958 - 960. [Full Text] [PDF]
|
|